Expression of MMP-2 and TIMP-1 in Renal Tissue of Patients with Chronic Active Antibody-mediated Renal Graft Rejection

Diagnostic Pathology

Hao Luo¹  Guimian Zou³  Hequn Zou²  Baoyao Wang³  Weiguo Sui³  Qiang Yan³ 

[1] First Clinical College of Southern Medical University, Guangzhou, 510515, China;Institute of Nephrology and Urology, Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China;Dialysis and Kidney Transplantation Center of PLA, 181 Hospital of PLA, Guilin, 541002, China

关键词: Interstitial fibrosis and tubular atrophy;    Chronic active antibody-mediate rejection;    Tissue inhibitor of metalloproteinase-1;    Matrix metalloproteinase-2;   

Others  :  807920
DOI  :  10.1186/1746-1596-7-141

 received in 2012-07-08, accepted in 2012-09-13,  发布年份 2012

【 摘 要 】

Objective

To investigate the expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metallopropteinase-1 (TIMP-1) in the renal allografts of patients with chronic active antibody-mediated rejection (AMR), and to explore their role in the pathogenesis of AMR.

Methods

Immunohistochemistry assay and computer-assisted image analysis were used to detect the expression of MMP-2 and TIMP-1 in the renal allografts with interstitial fibrosis and tubular atrophy (IF/TA) in 46 transplant recipients and 15 normal renal tissue specimens as the controls. The association of the expression level of either MMP-2 or TIMP-1 with the pathological grade of IF/TA in AMR was analyzed.

Results

The expression of either MMP-2 or TIMP-1 was significantly increased in the renal allografts of the recipients as compared with the normal renal tissue (P < 0.05). MMP-2 expression tended to decrease, while TIMP-1 and serum creatinine increased along with the increase of pathological grade of IF/TA (P < 0.05). In IF/TA groups, the expression of TIMP-1 was positively correlated to serum creatinine level (r = 0.718, P < 0.05).

Conclusions

It is suggested by the results that abnormal expressions of MMP-2 and TIMP-1 might play roles in the development of renal fibrosis in chronic AMR.

Virtual Slides

The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1128474926172838 webcite

【 授权许可】

   
2012 Yan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 1.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

【 参考文献 】

• [1]Feucht HE, Schneeberger H, Hillebrand G, et al.: Capillary deposition of C4d complements fragment and early renal graft loss. Kidney Int 1993, 43(6):1333-1338.
• [2]Solez K, Colvin RB, Racusen LC, et al.: Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008, 8(4):753-760.
• [3]Mackay AR, Gomez DE, Cottam DW, et al.: Identification of the 72-kDa (MMP-2) and 92-kDa (MMP-9) gelatinase/type IV collagenase in preparations of laminin and Matrigel. Biotechniques 1993, 15(6):1048-1051.
• [4]Cheng S, Pollock AS, Mahimkar R, et al.: Matrix metalloproteinase and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006, 20(11):1898-1900.
• [5]Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, et al.: Glucoseinduced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003, 284(4):671-679.
• [6]Berthier CC, Lods N, Joosten SA, et al.: Differential regulation of metzincins in experimental chronic renal allograft rejection: potential markers and novel therapeutic targets. Kidney Int 2006, 69(2):358-368.
• [7]Cai G, Zhang X, Hong Q, et al.: Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Nephrol Dial Transplant 2008, 23(6):1861-1875.
• [8]Wagrowska-Danilewicz M, Danilewicz M: Dys- regulation of immunoexpression of matrix metalloproteinases in renal chronic allograft injury. Pol J Pathol 2009, 60(2):88-93.
• [9]Qin YH, Lei FY, Hu P, et al.: Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis. Pediatr Nephrol 2009, 24(8):1477-1486.